BioCryst Pharmaceuticals | Capitale Di Prestito





Capitale Di Prestito Cambiamento Data
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
BioCryst Pharmaceuticals USD 194.37M 48.43M 2025-09
Chugai Pharma JPY 4.53B 1.95B 2024-12
Daiichi Sankyo JPY 300.15B 199.41B 2025-12
DBV Technologies USD 0 0 2025-03
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 22.14B 5M 2025-09
GlaxoSmithKline GBP 14.71B 186M 2025-12
Glaxosmithkline GBP 20.02B 4.72B 2025-09
Incyte USD 30.2M 5.17M 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
Karyopharm Therapeutics USD -0.93 0.67 2024-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novavax USD 223.63M 187K 2024-09
PTC Therapeutics USD 2.03B 193.22M 2025-12
Regeneron Pharmaceuticals USD 2.71B 720.4M 2025-12
Roche Holding CHF 27.43B 966M 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03


BioCryst Pharmaceuticals Capitale Di Prestito - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2026.